Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/28/2006 First Published: 3/1/1999


1.		Phase I/II Study of Ras Peptide Cancer Vaccine With or Without Interleukin-2 in HLA-A2-1-Positive Patients With Locally Advanced or Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Over 18				NCI				NCI-99-C-0023L NCI-T98-0034, NCT00019591, T98-0034

Last Modified: 4/20/2007


2.		Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines With or Without Cellular Immunotherapy With Peptide-Activated Lymphocytes Plus Interleukin-2 in Patients With Tumors Expressing Mutant p53 or ras

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-95-C-0105A NCI-T94-0096N, T94-0096, NCT00019084

Last Modified: 4/20/2007


3.		Phase II Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in Combination With Interleukin-2 and/or Sargramostim (GM-CSF) in Adults With Metastatic Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-97-C-0141F NCI-T96-0078, T96-0078, NCT00019331

Last Modified: 4/20/2007


4.		Phase I Pilot Study of Adjuvant Vaccine Therapy With Tumor-Specific Mutated ras Peptides in Patients With Colorectal, Pancreatic, Lung, Breast, or Prostate Cancer (Summary Last Modified 05/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				NCI-94-C-0096D NCI-T93-0152N, T93-0152, NCT00019006

Last Modified: 3/1/1998


5.		Phase IB Study of Vaccination with a Recombinant Mutant ras Protein with the Immunologic Adjuvant QS21 in Patients with Adenocarcinomas Expressing an Activated ras Oncoprotein (Summary Last Modified 03/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				over 18				NCI				NCI-97-C-0018 CRB-9411, NCI-NMOB-9608, NCI-T95-0048N, T95-0048

Last Modified: 12/1/2001 First Published: 9/1/1999


6.		Phase I Pilot Study of Ras Peptide Cancer Vaccine in Patients with Myelodysplastic Syndrome (Summary Last Modified 12/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				Over 17				NCI				MSKCC-98037 NCI-G99-1542, NCT00003959

Last Modified: 9/1/2001 First Published: 5/1/2000


7.		Phase I Pilot Study of Ras Peptide Cancer Vaccine and Sargramostim (GM-CSF) in Patients With Stage IB-IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				Over 17				NCI				MSKCC-99028 NCI-G00-1775, NCT00005630

Last Modified: 4/20/2007 First Published: 10/1/2000


8.		Phase I Study of Ras Peptide Cancer Vaccine Plus Immunological Adjuvant QS21 in Patients With Advanced Pancreatic or Colorectal Adenocarcinoma (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				FCCC-98026 NCI-T97-0051, NCT00006387, T97-0051

Select All on One Page